Natalia Buza, MD

• Akiko Iwasaki
• Alessandro Santin
• Amy Stiegler
• Austin McHenry
• Burak Zeybek
• Elena Ratner
• Gang Peng
• Gary Altwerger
• Gloria Huang
• Gulden Menderes
• Hongyan Chai
• Hugh Taylor
• Joan Tymon-Rosario
• Joseph Schlessinger
• Justin Harold
• Kaya Bilguvar
• Levent Mutlu
• Lingeng Lu
• Masoud Azodi
• Minhua Wang
• Mitchell Clark
• Pei Hui
• Peining Li
• Peter Schwartz
• Po-Han Chen
• Richard Lifton
• Rita Abi Raad
• Serena Wong
• Sergio Pecorelli
• Shari Damast
• Stefania Bellone
• Titus Boggon
• Vaagn Andikyan
• Yong Kong

Uterine Cervical Neoplasms; Ovarian Neoplasms; Uterine Neoplasms; Vulvar Neoplasms; Pathological Conditions, Anatomical; Gestational Trophoblastic Disease; Morphological and Microscopic Findings

• Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing.Chen PH, Hui P, Buza N. Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2020, 39: 193-198. PMID: 30676431, DOI: 10.1097/PGP.0000000000000579.
• Extragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell Origin.Simpson S, Simoni M, Hui P, Taylor H, Buza N. Extragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell Origin. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2020, 39: 247-253. PMID: 31033797, DOI: 10.1097/PGP.0000000000000601.
• HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2020, 33: 118-127. PMID: 31477811, DOI: 10.1038/s41379-019-0358-x.
• Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology 2020, 157: 161-166. PMID: 31924334, PMCID: PMC7127981, DOI: 10.1016/j.ygyno.2019.12.034.
• Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients.Wong S, Hui P, Buza N. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2020, 33: 1172-1181. PMID: 31932681, DOI: 10.1038/s41379-020-0455-x.
• Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma.Pelligra S, Buza N, Hui P, Bellone S, Zeybek B, Ratner E, Schwartz PE, Scambia G, Santin AD. Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. Gynecologic Oncology Reports 2020, 32: 100554. PMID: 32140533, PMCID: PMC7049633, DOI: 10.1016/j.gore.2020.100554.
• Molecular and clinicopathologic characterization of intravenous leiomyomatosis.Ordulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2020, 33: 1844-1860. PMID: 32341498, PMCID: PMC7483566, DOI: 10.1038/s41379-020-0546-8.
• HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.Buza N. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand. Archives Of Pathology & Laboratory Medicine 2021, 145: 687-691. PMID: 32649220, DOI: 10.5858/arpa.2020-0207-RA.
• Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.
• Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.Rottmann D, Assem H, Matsumoto N, Wong S, Hui P, Buza N. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2021, 40: 263-271. PMID: 32897955, DOI: 10.1097/PGP.0000000000000690.
• Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation.Wu X, Snir O, Rottmann D, Wong S, Buza N, Hui P. Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2019, 32: 650-658. PMID: 30443012, DOI: 10.1038/s41379-018-0179-3.
• Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles.Buza N, McGregor SM, Barroilhet L, Zheng X, Hui P. Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2019, 32: 1180-1188. PMID: 30952972, DOI: 10.1038/s41379-019-0266-0.
• Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women.Buza N, Baine I, Hui P. Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2019, 32: 1271-1280. PMID: 31028360, DOI: 10.1038/s41379-019-0275-z.
• Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls.Buza N. Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls. Archives Of Pathology & Laboratory Medicine 2019, 143: 47-64. PMID: 30785337, DOI: 10.5858/arpa.2018-0289-RA.
• Ovarian Teratomas in Women With Anti-N-methyl-D-Aspartate Receptor Encephalitis: Topography and Composition of Immune Cell and Neuroglial Populations Is Compatible With an Autoimmune Mechanism of Disease.Nolan A, Buza N, Margeta M, Rabban JT. Ovarian Teratomas in Women With Anti-N-methyl-D-Aspartate Receptor Encephalitis: Topography and Composition of Immune Cell and Neuroglial Populations Is Compatible With an Autoimmune Mechanism of Disease. The American Journal Of Surgical Pathology 2019, 43: 949-964. PMID: 31021857, DOI: 10.1097/PAS.0000000000001249.
• Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.
• Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes.Wong S, Ratner E, Buza N. Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes. Histopathology 2018, 73: 109-123. PMID: 29484698, DOI: 10.1111/his.13503.
• Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix.Wong S, Hong W, Hui P, Buza N. Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2017, 36: 101-106. PMID: 27362905, DOI: 10.1097/PGP.0000000000000309.
• Mismatch repair deficiency testing in clinical practice.Buza N, Ziai J, Hui P. Mismatch repair deficiency testing in clinical practice. Expert Review Of Molecular Diagnostics 2016, 16: 591-604. PMID: 26895074, DOI: 10.1586/14737159.2016.1156533.
• Diagnostic application of KRAS mutation testing in uterine microglandular proliferations.Hong W, Abi-Raad R, Alomari AK, Hui P, Buza N. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. Human Pathology 2015, 46: 1000-5. PMID: 25997988, DOI: 10.1016/j.humpath.2015.03.010.
• Intravenous leiomyomatosis revisited: an experience of 14 cases at a single medical center.Carr RJ, Hui P, Buza N. Intravenous leiomyomatosis revisited: an experience of 14 cases at a single medical center. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2015, 34: 169-76. PMID: 25675187, DOI: 10.1097/PGP.0000000000000127.
• Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study.Buza N, Xu F, Wu W, Carr RJ, Li P, Hui P. Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study. Human Pathology 2014, 45: 1885-92. PMID: 25033729, DOI: 10.1016/j.humpath.2014.05.010.
• Genotyping diagnosis of nongestational choriocarcinoma involving fallopian tube and broad ligament: a case study.Buza N, Rutherford T, Hui P. Genotyping diagnosis of nongestational choriocarcinoma involving fallopian tube and broad ligament: a case study. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2014, 33: 58-63. PMID: 24300537, DOI: 10.1097/PGP.0b013e31827cd386.
• Mitotically active microglandular hyperplasia of the cervix: a case series with implications for the differential diagnosis.Abi-Raad R, Alomari A, Hui P, Buza N. Mitotically active microglandular hyperplasia of the cervix: a case series with implications for the differential diagnosis. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2014, 33: 524-30. PMID: 25083971, DOI: 10.1097/PGP.0000000000000086.
• HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.Buza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Archives Of Pathology & Laboratory Medicine 2014, 138: 343-50. PMID: 24576030, DOI: 10.5858/arpa.2012-0416-RA.
• HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.Buza N. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2021, 40: 17-23. PMID: 33290351, DOI: 10.1097/PGP.0000000000000711.
• Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.Buza N, Euscher ED, Matias-Guiu X, McHenry A, Oliva E, Ordulu Z, Parra-Herran C, Rottmann D, Turner BM, Wong S, Hui P. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2021, 34: 1194-1202. PMID: 33536574, DOI: 10.1038/s41379-021-00746-5.
• HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma.Cagaanan A, Stelter B, Vu N, Rhode EN, Stewart T, Hui P, Buza N, Al-Niaimi A, Flynn C, Weisman PS, McGregor SM. HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma. International Journal Of Gynecological Pathology : Official Journal Of The International Society Of Gynecological Pathologists 2022, 41: 132-141. PMID: 33782344, DOI: 10.1097/PGP.0000000000000783.
• Integrated mutational landscape analysis of uterine leiomyosarcomas.Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118 PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
• A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi DA, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2021, 32: 1045-1046. PMID: 33932502, DOI: 10.1016/j.annonc.2021.04.013.
• Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine.Buza N, Hui P. Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2021, 34: 1658-1672. PMID: 34088998, DOI: 10.1038/s41379-021-00831-9.
• DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.
• Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship.Assem H, Rottmann D, Finkelstein A, Wang M, Ratner E, Santin AD, Buza N, Hui P. Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. Human Pathology 2021, 118: 1-8. PMID: 34508766, DOI: 10.1016/j.humpath.2021.09.001.
• Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors.Buza N. Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors. Seminars In Diagnostic Pathology 2022, 39: 58-77. PMID: 34750021, DOI: 10.1053/j.semdp.2021.10.006.
• A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi DA, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario JR, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 2022, 128: 1206-1218. PMID: 34875107, DOI: 10.1002/cncr.34025.
• Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites.Li JY, Mutlu L, Tymon-Rosario J, Khadraoui W, Nagarkatti N, Hui P, Buza N, Lu L, Schwartz P, Menderes G. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecologic Oncology Reports 2022, 39: 100913. PMID: 35005157, PMCID: PMC8715286, DOI: 10.1016/j.gore.2021.100913.
• Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022 PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.